



# Iowa Department of Human Services

Kim Reynolds  
Governor

Adam Gregg  
Lt. Governor

Jerry R. Foxhoven  
Director

## Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

October 4, 2017

**Location: Mid-Iowa Council  
Fred Maytag II Scout Center  
6123 Scout Trail  
Des Moines, Iowa, 50321  
Room 3**

**Time: 9:30 a.m. – 1:30 p.m.**

### Final Agenda

1. Welcome & Introductions
  - a) Commission Members and Staff
2. Commission Business
  - a) Approval of the Minutes
  - b) Annual DUR Commission Chairperson and Vice Chairperson Elections
  - c) DHS Recommendation Letter – August 2017
  - d) P&T Recommendation Letter – August 2017
  - e) [HF653](#) Process – Biologics and Genetically Targeted Drugs
  - f) DUR Response for [HF653](#) Report - Step Therapy Protocol for Prescription Drugs See [HF233](#)
3. IME Pharmacy Update
4. Fee-for-Service Program Prevalence Report Summary
5. MCO Prevalence Report Summary and Updates
  - a) AmeriHealth Caritas Iowa
  - b) Amerigroup
  - c) United Healthcare Community Plan
6. Public Comment\* (See Conflict of Interest Disclosure Form)
7. ProDUR Edits
  - a) Tramadol Age Edit – Second Review
8. Prior Authorization
  - a) Annual Review of Prior Authorization Criteria

- b) Buprenorphine/Naloxone – Initial Review
- c) Smoking Cessation Therapy, Oral & Nicotine Replacement Therapy – Initial Review
- d) Biologicals for Ankylosing Spondylitis – Initial Review
- e) Biologicals for Arthritis – Initial Review
- f) Biologicals for Inflammatory Bowel Disease – Initial Review
- g) Biologicals for Plaque Psoriasis – Initial Review
- h) Tramadol or Codeine in Members < 18 – Initial Review
- i) Sacubitril/Valsartan – (Entresto) Initial Review
- j) Dupilumab (Dupixent) – Second Review

9. Miscellaneous

- a) DUR Digest Vol. 30, No. 1 – Second Review
- b) MedWatch
- c) Articles of Interest
  - i. Friends or foes: Is empathy necessary for moral behavior?  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241340/>
  - ii. New treatments for serious conditions: ethical implications  
<https://www.ncbi.nlm.nih.gov/pubmed/28467402>

10. Adjournment

\*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

**[www.iadur.org](http://www.iadur.org)**

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at [info@iadur.org](mailto:info@iadur.org) or (515) 974-3131

**\*\*\*Next Meeting December 6, 2017\*\*\*  
Learning Resource Center  
3550 Mills Civic Parkway, West Des Moines, IA**